Vivendy Therapeutics

Vivet Therapeutics is a clinical-stage biotechnology company specializing in the development of novel gene therapies for rare inherited metabolic liver diseases. Founded in 2016 and headquartered in Paris, the company leverages a proprietary liver-directed adeno-associated virus (AAV) platform to address significant unmet medical needs. Its lead program, VTX-801, is currently in clinical development for the treatment of Wilson disease, a life-threatening condition caused by copper accumulation. Vivet's pipeline also includes programs targeting Progressive Familial Intrahepatic Cholestasis (PFIC) and Citrullinemia. The company has established a strategic partnership with Pfizer, which holds a minority stake and an option to acquire the company.